ScripAfter a torrid year that began with the late-stage failure of its knee osteoarthritis program, Bone Therapeutics SA hopes to have secured its survival through a reverse merger with France's Medseni
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Novo Nordisk, Flagship Hope Combined Ef
ScripThe announcement that France's Hybrigenics Pharma would like to merge with Bone Therapeutics SA surprised many observers, not least Miguel Forte, CEO of the Belgian regenerative medicine company w
ScripThe table records clinical developments using data from Informa Pharma Intelligence’s Biomedtracker. It lists drugs for which an important event was recorded between Feb. 3 and Feb. 9, 2017, divided b